Sign In

Login

Password

Forgot Password ? Sign Up

Włókniakomięsak guzowaty skóry (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Włókniakomięsak guzowaty skóry" in Polish language version.

refsWebsite
Global rank Polish rank
42nih.gov
4th place
7th place
33doi.org
2nd place
6th place

doi.org

doi.org

  • K. Thway, J. Noujaim, R. L. Jones, C. Fisher. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. „Ann Diagn Pathol”. 25, s. 64-71, 2016. DOI: 10.1016/j.anndiagpath.2016.09.013. PMID: 27806849. 
  • B. Llombart, C. Serra-Guillén, C. Monteagudo, JA. López Guerrero i inni. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. „Semin Diagn Pathol”. 30 (1), s. 13-28, 2013. DOI: 10.1053/j.semdp.2012.01.002. PMID: 23327727. 
  • B. Bogucki, I. Neuhaus, E. A. Hurst. Dermatofibrosarcoma protuberans: a review of the literature. „Dermatol Surg”. 38 (4), s. 537-551, 2012. DOI: 10.1111/j.1524-4725.2011.02292.x. PMID: 22288484. 
  • V. D. Criscione, M. A. Weinstock. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. „J Am Acad Dermatol”. 56 (6), s. 968-973, 2007. DOI: 10.1016/j.jaad.2006.09.006. PMID: 17141362. 
  • W. M. Mendenhall, R. A. Zlotecki, M. T. Scarborough. Dermatofibrosarcoma protuberans. „Cancer”. 101 (11), s. 2503-2508, 2004. DOI: 10.1002/cncr.20678. PMID: 15503305. 
  • R. M. Minter, J. D. Reith, S. N. Hochwald. Metastatic potential of dermatofibrosarcoma protuberans with fibrosarcomatous change. „J Surg Oncol”. 82 (3), s. 201-208, 2003. DOI: 10.1002/jso.10211. PMID: 12619065. 
  • J. L. Kampshoff, T. H. Cogbill. Unusual skin tumors: Merkel cell carcinoma, eccrine carcinoma, glomus tumors, and dermatofibrosarcoma protuberans. „Surg Clin North Am”. 89 (3), s. 727-738, 2009. DOI: 10.1016/j.suc.2009.02.005. PMID: 19465208. 
  • P. Saiag, J. J. Grob, C. Lebbe, J. Malvehy i inni. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. „Eur J Cancer”. 51 (17), s. 2604-2608, 2015. DOI: 10.1016/j.ejca.2015.06.108. PMID: 26189684. 
  • T. Takahira, Y. Oda, S. Tamiya, K. Higaki i inni. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. „Mod Pathol”. 20 (6), s. 668-675, 2007. DOI: 10.1038/modpathol.3800783. PMID: 17431412. 
  • J. Andrae, R. Gallini, C. Betsholtz. Role of platelet-derived growth factors in physiology and medicine. „Genes Dev”. 22 (10), s. 1276-1312, 2008. DOI: 10.1101/gad.1653708. PMID: 18483217. 
  • P. Rutkowski, M. Debiec-Rychter. Current treatment options for dermatofibrosarcoma protuberans. „Expert Rev Anticancer Ther”. 15 (8), s. 901-909, 2015. DOI: 10.1586/14737140.2015.1052799. PMID: 26027711. 
  • M. Lisovsky, M. P. Hoang, K. A. Dresser, P. Kapur i inni. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. „Mod Pathol”. 21 (1), s. 31-38, 2008. DOI: 10.1038/modpathol.3800971. PMID: 17885669. 
  • K. U. Patel, S. S. Szabo, V. S. Hernandez, V. G. Prieto i inni. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. „Hum Pathol”. 39 (2), s. 184-193, 2008. DOI: 10.1016/j.humpath.2007.06.009. PMID: 17950782. 
  • R. Salgado, B. Llombart, R. M Pujol, A. Fernández-Serra i inni. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. „Genes Chromosomes Cancer”. 50 (7), s. 510-517, 2011. DOI: 10.1002/gcc.20874. PMID: 21484928. 
  • J. M. Farma, J. B. Ammori, J. S. Zager, SS. Marzban i inni. Dermatofibrosarcoma protuberans: how wide should we resect?. „Ann Surg Oncol”. 17 (8), s. 2112-2118, 2010. DOI: 10.1245/s10434-010-1046-8. PMID: 20354798. 
  • A. N. Meguerditchian, J. Wang, B. Lema, WG. Kraybill i inni. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. „Am J Clin Oncol”. 33 (3), s. 300-303, 2010. DOI: 10.1097/COC.0b013e3181aaca87. PMID: 19858696. 
  • S. T. Heuvel, A. Suurmeijer, E. Pras, R. J. Van Ginkel i inni. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. „Eur J Surg Oncol”. 36 (1), s. 89-94, 2010. DOI: 10.1016/j.ejso.2009.07.006. PMID: 19646839. 
  • C. K. Chang, I. A. Jacobs, G. I. Salti. Outcomes of surgery for dermatofibrosarcoma protuberans. „Eur J Surg Oncol”. 30 (3), s. 341-345, 2004. DOI: 10.1016/j.ejso.2003.12.005. PMID: 15028319. 
  • M. Fiore, R. Miceli, C. Mussi, S. Lo Vullo i inni. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. „J Clin Oncol”. 23 (30), s. 7669-7675, 2005. DOI: 10.1200/JCO.2005.02.5122. PMID: 16234529. 
  • M. Foroozan, J. F. Sei, M. Amini, A. Beauchet i inni. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. „Arch Dermatol”. 148 (9), s. 1055-1063, 2012. DOI: 10.1001/archdermatol.2012.1440. PMID: 22986859. 
  • G. A. McArthur, G. D. Demetri, A. van Oosterom, M. C. Heinrich i inni. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. „J Clin Oncol”. 23 (4), s. 866-873, 2005. DOI: 10.1200/JCO.2005.07.088. PMID: 15681532. 
  • P. Rutkowski, M. Dębiec-Rychter, Z. Nowecki, W. Michej i inni. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. „J Eur Acad Dermatol Venereol”. 25 (3), s. 264-270, 2011. DOI: 10.1111/j.1468-3083.2010.03774.x. PMID: 20569296. 
  • S. Ugurel, T. Mentzel, J. Utikal, P. Helmbold i inni. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. „Clin Cancer Res”. 20 (2), s. 499-510, 2014. DOI: 10.1158/1078-0432.CCR-13-1411. PMID: 24173542. 
  • D. Kérob, R. Porcher, O. Vérola, S. Dalle i inni. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. „Clin Cancer Res”. 16 (12), s. 3288-3295, 2010. DOI: 10.1158/1078-0432.CCR-09-3401. PMID: 20439456. 
  • K. O. Castle, B. A. Guadagnolo, C. J. Tsai, B. W. Feig i inni. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. „Int J Radiat Oncol Biol Phys”. 86 (3), s. 585-590, 2013. DOI: 10.1016/j.ijrobp.2013.02.024. PMID: 23628134. 
  • N. Williams, C. G. Morris, J. M. Kirwan, R. Dagan i inni. Radiotherapy for dermatofibrosarcoma protuberans. „Am J Clin Oncol”. 37 (5), s. 430-432, 2014. DOI: 10.1097/COC.0b013e31827dee86. PMID: 23388563. 
  • K. L. Kreicher, D. E. Kurlander, H. R. Gittleman, J. S. Barnholtz-Sloan i inni. Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. „Dermatol Surg”. 42 Suppl 1, 2016. DOI: 10.1097/DSS.0000000000000300. PMID: 26730971. 
  • M. C. Criscito, K. J. Martires, J. A. Stein. Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans. „JAMA Dermatol”. 152 (12), s. 1365-1371, 2016. DOI: 10.1001/jamadermatol.2016.1886. PMID: 27262160. 

dx.doi.org

  • Nikolaos Angouridakis i inni, Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck, „Head Neck Oncol”, 3, 2011, s. 5, DOI: 10.1186/1758-3284-3-5, PMID: 21294902, PMCID: PMC3038985.
  • Ryan C. Fields i inni, Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy, „Annals of Surgical Oncology”, 18 (2), 2011, s. 328-336, DOI: 10.1245/s10434-010-1316-5, PMID: 20844969, PMCID: PMC4310211.
  • Piotr Rutkowski i inni, Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials, „Journal of Clinical Oncology”, 28 (10), 2010, s. 1772-1779, DOI: 10.1200/JCO.2009.25.7899, PMID: 20194851, PMCID: PMC3040044.
  • Francois G Kamar, Victor F Kairouz, Alain N Sabri, Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report, „Clinical Sarcoma Research”, 3 (1), 2013, s. 5, DOI: 10.1186/2045-3329-3-5, PMID: 23557478, PMCID: PMC3637545.
  • Robert M Corey, Katrina Swett, William G Ward, Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report, „Cancer Med”, 3 (5), 2014, s. 1404-1415, DOI: 10.1002/cam4.288, PMID: 25044961, PMCID: PMC4302691.

nih.gov

ncbi.nlm.nih.gov

  • K. Thway, J. Noujaim, R. L. Jones, C. Fisher. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. „Ann Diagn Pathol”. 25, s. 64-71, 2016. DOI: 10.1016/j.anndiagpath.2016.09.013. PMID: 27806849. 
  • B. Llombart, C. Serra-Guillén, C. Monteagudo, JA. López Guerrero i inni. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. „Semin Diagn Pathol”. 30 (1), s. 13-28, 2013. DOI: 10.1053/j.semdp.2012.01.002. PMID: 23327727. 
  • B. Bogucki, I. Neuhaus, E. A. Hurst. Dermatofibrosarcoma protuberans: a review of the literature. „Dermatol Surg”. 38 (4), s. 537-551, 2012. DOI: 10.1111/j.1524-4725.2011.02292.x. PMID: 22288484. 
  • V. D. Criscione, M. A. Weinstock. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. „J Am Acad Dermatol”. 56 (6), s. 968-973, 2007. DOI: 10.1016/j.jaad.2006.09.006. PMID: 17141362. 
  • TY. Chuang, W. P. Su, S. A. Muller. Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. „J Am Acad Dermatol”. 23, s. 254-256, 1990. PMID: 2170468. 
  • W. B. Bowne, C. R. Antonescu, D. H. Leung, S. C. Katz i inni. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. „Cancer”. 88 (12), s. 2711-2720, 2000. PMID: 10870053. 
  • W. M. Mendenhall, R. A. Zlotecki, M. T. Scarborough. Dermatofibrosarcoma protuberans. „Cancer”. 101 (11), s. 2503-2508, 2004. DOI: 10.1002/cncr.20678. PMID: 15503305. 
  • Nikolaos Angouridakis i inni, Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck, „Head Neck Oncol”, 3, 2011, s. 5, DOI: 10.1186/1758-3284-3-5, PMID: 21294902, PMCID: PMC3038985.
  • R. M. Minter, J. D. Reith, S. N. Hochwald. Metastatic potential of dermatofibrosarcoma protuberans with fibrosarcomatous change. „J Surg Oncol”. 82 (3), s. 201-208, 2003. DOI: 10.1002/jso.10211. PMID: 12619065. 
  • J. Ding, H. Hashimoto, M. Enjoji. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors.. „Cancer”. 64 (3), s. 721-729, 1989. PMID: 2545326. 
  • T. Mentzel, A. Beham, D. Katenkamp, A. P. Dei Tos i inni. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. „Am J Surg Pathol”. 22 (5), s. 576-587, 1998. PMID: 9591728. 
  • J. J. Abbott, A. M. Oliveira, AG. Nascimento. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. „Am J Surg Pathol”. 30 (4), s. 436-443, 2006. PMID: 16625088. 
  • J. L. Kampshoff, T. H. Cogbill. Unusual skin tumors: Merkel cell carcinoma, eccrine carcinoma, glomus tumors, and dermatofibrosarcoma protuberans. „Surg Clin North Am”. 89 (3), s. 727-738, 2009. DOI: 10.1016/j.suc.2009.02.005. PMID: 19465208. 
  • P. Saiag, J. J. Grob, C. Lebbe, J. Malvehy i inni. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. „Eur J Cancer”. 51 (17), s. 2604-2608, 2015. DOI: 10.1016/j.ejca.2015.06.108. PMID: 26189684. 
  • T. Takahira, Y. Oda, S. Tamiya, K. Higaki i inni. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. „Mod Pathol”. 20 (6), s. 668-675, 2007. DOI: 10.1038/modpathol.3800783. PMID: 17431412. 
  • C. H. Heldin, B. Westermark. Mechanism of action and in vivo role of platelet-derived growth factor. „Physiol Rev”. 79 (4), s. 1283-1316, 1999. PMID: 10508235. 
  • J. Andrae, R. Gallini, C. Betsholtz. Role of platelet-derived growth factors in physiology and medicine. „Genes Dev”. 22 (10), s. 1276-1312, 2008. DOI: 10.1101/gad.1653708. PMID: 18483217. 
  • P. Rutkowski, M. Debiec-Rychter. Current treatment options for dermatofibrosarcoma protuberans. „Expert Rev Anticancer Ther”. 15 (8), s. 901-909, 2015. DOI: 10.1586/14737140.2015.1052799. PMID: 26027711. 
  • M. Lisovsky, M. P. Hoang, K. A. Dresser, P. Kapur i inni. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. „Mod Pathol”. 21 (1), s. 31-38, 2008. DOI: 10.1038/modpathol.3800971. PMID: 17885669. 
  • R. B. West, J. Harvell, S. C. Linn, C. L. Liu i inni. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. „Am J Surg Pathol”. 28 (8), s. 1063-1069, Aug 2004. PMID: 15252314. 
  • K. U. Patel, S. S. Szabo, V. S. Hernandez, V. G. Prieto i inni. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. „Hum Pathol”. 39 (2), s. 184-193, 2008. DOI: 10.1016/j.humpath.2007.06.009. PMID: 17950782. 
  • R. Salgado, B. Llombart, R. M Pujol, A. Fernández-Serra i inni. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. „Genes Chromosomes Cancer”. 50 (7), s. 510-517, 2011. DOI: 10.1002/gcc.20874. PMID: 21484928. 
  • J. M. Farma, J. B. Ammori, J. S. Zager, SS. Marzban i inni. Dermatofibrosarcoma protuberans: how wide should we resect?. „Ann Surg Oncol”. 17 (8), s. 2112-2118, 2010. DOI: 10.1245/s10434-010-1046-8. PMID: 20354798. 
  • Ryan C. Fields i inni, Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy, „Annals of Surgical Oncology”, 18 (2), 2011, s. 328-336, DOI: 10.1245/s10434-010-1316-5, PMID: 20844969, PMCID: PMC4310211.
  • A. N. Meguerditchian, J. Wang, B. Lema, WG. Kraybill i inni. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. „Am J Clin Oncol”. 33 (3), s. 300-303, 2010. DOI: 10.1097/COC.0b013e3181aaca87. PMID: 19858696. 
  • S. T. Heuvel, A. Suurmeijer, E. Pras, R. J. Van Ginkel i inni. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. „Eur J Surg Oncol”. 36 (1), s. 89-94, 2010. DOI: 10.1016/j.ejso.2009.07.006. PMID: 19646839. 
  • C. K. Chang, I. A. Jacobs, G. I. Salti. Outcomes of surgery for dermatofibrosarcoma protuberans. „Eur J Surg Oncol”. 30 (3), s. 341-345, 2004. DOI: 10.1016/j.ejso.2003.12.005. PMID: 15028319. 
  • M. Fiore, R. Miceli, C. Mussi, S. Lo Vullo i inni. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. „J Clin Oncol”. 23 (30), s. 7669-7675, 2005. DOI: 10.1200/JCO.2005.02.5122. PMID: 16234529. 
  • M. Foroozan, J. F. Sei, M. Amini, A. Beauchet i inni. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. „Arch Dermatol”. 148 (9), s. 1055-1063, 2012. DOI: 10.1001/archdermatol.2012.1440. PMID: 22986859. 
  • T. Sjöblom, A. Shimizu, K. P. O'Brien, K. Pietras i inni. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. „Cancer Res”. 61 (15), s. 5778-5783, 2001. PMID: 11479215. 
  • G. A. McArthur, G. D. Demetri, A. van Oosterom, M. C. Heinrich i inni. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. „J Clin Oncol”. 23 (4), s. 866-873, 2005. DOI: 10.1200/JCO.2005.07.088. PMID: 15681532. 
  • P. Rutkowski, M. Dębiec-Rychter, Z. Nowecki, W. Michej i inni. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. „J Eur Acad Dermatol Venereol”. 25 (3), s. 264-270, 2011. DOI: 10.1111/j.1468-3083.2010.03774.x. PMID: 20569296. 
  • Piotr Rutkowski i inni, Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials, „Journal of Clinical Oncology”, 28 (10), 2010, s. 1772-1779, DOI: 10.1200/JCO.2009.25.7899, PMID: 20194851, PMCID: PMC3040044.
  • Francois G Kamar, Victor F Kairouz, Alain N Sabri, Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report, „Clinical Sarcoma Research”, 3 (1), 2013, s. 5, DOI: 10.1186/2045-3329-3-5, PMID: 23557478, PMCID: PMC3637545.
  • S. Ugurel, T. Mentzel, J. Utikal, P. Helmbold i inni. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. „Clin Cancer Res”. 20 (2), s. 499-510, 2014. DOI: 10.1158/1078-0432.CCR-13-1411. PMID: 24173542. 
  • D. Kérob, R. Porcher, O. Vérola, S. Dalle i inni. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. „Clin Cancer Res”. 16 (12), s. 3288-3295, 2010. DOI: 10.1158/1078-0432.CCR-09-3401. PMID: 20439456. 
  • K. O. Castle, B. A. Guadagnolo, C. J. Tsai, B. W. Feig i inni. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. „Int J Radiat Oncol Biol Phys”. 86 (3), s. 585-590, 2013. DOI: 10.1016/j.ijrobp.2013.02.024. PMID: 23628134. 
  • N. Williams, C. G. Morris, J. M. Kirwan, R. Dagan i inni. Radiotherapy for dermatofibrosarcoma protuberans. „Am J Clin Oncol”. 37 (5), s. 430-432, 2014. DOI: 10.1097/COC.0b013e31827dee86. PMID: 23388563. 
  • Robert M Corey, Katrina Swett, William G Ward, Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report, „Cancer Med”, 3 (5), 2014, s. 1404-1415, DOI: 10.1002/cam4.288, PMID: 25044961, PMCID: PMC4302691.
  • K. L. Kreicher, D. E. Kurlander, H. R. Gittleman, J. S. Barnholtz-Sloan i inni. Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. „Dermatol Surg”. 42 Suppl 1, 2016. DOI: 10.1097/DSS.0000000000000300. PMID: 26730971. 
  • M. C. Criscito, K. J. Martires, J. A. Stein. Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans. „JAMA Dermatol”. 152 (12), s. 1365-1371, 2016. DOI: 10.1001/jamadermatol.2016.1886. PMID: 27262160. 
  • H. B. Taylor, E. B. Helwig. Dermatofibrosarcoma protuberans. A study of 115 cases. „Cancer”. 15. s. 717-725. PMID: 13919964.